Cytogenetic landscape and impact in blast phase of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy

Risk stratification of chromosomal abnormalities in chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy

(2016) W. Wang et al.   BLOOD

The landscape of myeloid neoplasms with isochromosome 17q discloses a specific mutation profile and is characterized by an accumulation of prognostically adverse molecular markers

(2016) M Meggendorfer et al.   LEUKEMIA

Differential impact of additional chromosomal abnormalities in myeloid vs lymphoid blast phase of chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy

(2016) Z Chen et al.   LEUKEMIA

Management of chronic myeloid leukemia in blast crisis

(2015) S. Saußele et al.   ANNALS OF HEMATOLOGY

Causes of resistance and treatment choices of second- and third-line treatment in chronic myelogenous leukemia patients

(2015) Andreas Hochhaus et al.   ANNALS OF HEMATOLOGY

Impact of unbalanced minor route versus major route karyotypes at diagnosis on prognosis of CML

(2015) Alice Fabarius et al.   ANNALS OF HEMATOLOGY

A review of the European LeukemiaNet recommendations for the management of CML

(2015) Michele Baccarani et al.   ANNALS OF HEMATOLOGY

Clinical and prognostic significance of 3q26.2 and other chromosome 3 abnormalities in CML in the era of tyrosine kinase inhibitors

(2015) W. Wang et al.   BLOOD

Mutations in the BCR-ABL1 Kinase Domain and Elsewhere in Chronic Myeloid Leukemia

(2015) Simona Soverini et al.   Clinical Lymphoma Myeloma & Leukemia

Impact of trisomy 8 on treatment response and survival of patients with chronic myelogenous leukemia in the era of tyrosine kinase inhibitors

(2015) W Wang et al.   LEUKEMIA

Prognosis of long-term survival considering disease-specific death in patients with chronic myeloid leukemia

(2015) M Pfirrmann et al.   LEUKEMIA

Clonal Evolution and Blast Crisis Correlate with Enhanced Proteolytic Activity of Separase in BCR-ABL b3a2 Fusion Type CML under Imatinib Therapy

(2015) Wiltrud Haaß et al.   PLoS One

Clinicopathologic and molecular characterization of myeloid neoplasms harboring isochromosome 17(q10)

(2014) Valeria Visconte et al.   AMERICAN JOURNAL OF HEMATOLOGY

Molecular-defined clonal evolution in patients with chronic myeloid leukemia independent of the BCR-ABL status

(2014) M Schmidt et al.   LEUKEMIA

−7/7q− syndrome in myeloid-lineage hematopoietic malignancies: attempts to understand this complex disease entity

(2014) H Honda et al.   ONCOGENE

European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013

(2013) M. Baccarani et al.   BLOOD

Genomic instability may originate from imatinib-refractory chronic myeloid leukemia stem cells

(2013) E. Bolton-Gillespie et al.   BLOOD

Clonal evolution in hematological malignancies and therapeutic implications

(2013) D A Landau et al.   LEUKEMIA

Potential mechanisms of disease progression and management of advanced-phase chronic myeloid leukemia

(2013) Elias J. Jabbour et al.   LEUKEMIA & LYMPHOMA

Sole abnormalities of chromosome 7 in myeloid malignancies: Spectrum, histopathologic correlates, and prognostic implications

(2012) Fareeda Taher Nazer Hussain et al.   AMERICAN JOURNAL OF HEMATOLOGY

Additional chromosomal abnormalities in Philadelphia-positive clone: adverse prognostic influence on frontline imatinib therapy: a GIMEMA Working Party on CML analysis

(2012) S. Luatti et al.   BLOOD

On the Power of Additional and Complex Chromosomal Aberrations in CML

(2012) Karin M. Greulich-Bode et al.   CURRENT GENOMICS

Genetic Mechanisms of Chronic Myeloid Leukemia Blastic Transformation

(2012) Tomasz Skorski   Current Hematologic Malignancy Reports

Genomic Instability in Chronic Myeloid Leukemia: Targets for Therapy?

(2012) N. Muvarak et al.   Current Hematologic Malignancy Reports

Impact of additional cytogenetic aberrations at diagnosis on prognosis of CML: long-term observation of 1151 patients from the randomized CML Study IV

(2011) A. Fabarius et al.   BLOOD

BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet

(2011) S. Soverini et al.   BLOOD

Myeloid neoplasms with isolated isochromosome 17q represent a clinicopathologic entity associated with myelodysplastic/myeloproliferative features, a high risk of leukemic transformation, and wild-type TP53

(2011) Rashmi Kanagal-Shamanna et al.   CANCER

Impact ofBCR-ABLmutations on patients with chronic myeloid leukemia

(2011) Andreas Hochhaus et al.   CELL CYCLE

The Biology of Chronic Myelogenous Leukemia Progression: Who, What, Where, and Why?

(2011) Jerald P. Radich   HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA

Educational Session: Managing Chronic Myeloid Leukemia as a Chronic Disease

(2011) A. Hochhaus   Hematology-American Society of Hematology Education Program

Molecular Pathogenesis of Philadelphia-Positive Chronic Myeloid Leukemia – is it all BCR-ABL?

(2010) H. Rumpold et al.   CURRENT CANCER DRUG TARGETS

Current Treatment Concepts of CML

(2010) A. A. Leitner et al.   CURRENT CANCER DRUG TARGETS

Associations between imatinib resistance conferring mutations and Philadelphia positive clonal cytogenetic evolution in CML

(2010) Susanne Schnittger et al.   GENES CHROMOSOMES & CANCER

Similar patterns of chromosome abnormalities in CML occur in addition to the Philadelphia chromosome with or without tyrosine kinase inhibitor treatment

(2009) C Haferlach et al.   LEUKEMIA